{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-23-000029","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.167494+00:00","generated_at":"2026-06-11T07:40:14.097045+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia receives Nasdaq deficiency notice for late Q2 filing; plans to file by Aug 25","bullets":["Form 10-Q for Q2 2023 not filed on time; Nasdaq gave non-compliance notice on Aug 11, 2023.","Accounting errors identified regarding return reserves for Auryxia in prior financial statements.","Company has 60 days to submit a plan; expects to file Form 10-Q by August 25, 2023.","Common stock continues trading on Nasdaq; Akebia expects to regain compliance upon filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-23-000029","json":"https://secwatch.observer/filing/0001517022-23-000029.json","markdown":"https://secwatch.observer/filing/0001517022-23-000029.md","text":"https://secwatch.observer/filing/0001517022-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000029/0001517022-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000029/akba-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T07:40:14.097045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d1f2cc2c301334b6dd5d3daa757fab68f0f1749","claim":"Akebia Therapeutics, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 11, 2023, Akebia Therapeutics, Inc. (the “Company”) received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “Quarterly Report”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”). The Nasdaq notification letter specifies that the Company has 60 calendar days","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000029/0001517022-23-000029-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}